Report cover image

Melanoma Drugs Industry Research Report 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 127 Pages
SKU # APRC20542575

Description

Summary

According to APO Research, The global Melanoma Drugs market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Melanoma Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Melanoma Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Melanoma Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Melanoma Drugs include Grand Pharmaceutical (China) Co., Ltd, Innovent Biologics, Sanofi, Novartis, Merck Group, Roche, Shanghai Junshi Biosciences Co.,Ltd, Pfizer and Jiangsu Hengrui Medicine Co.,Ltd., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Melanoma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Melanoma Drugs.
The Melanoma Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Melanoma Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Melanoma Drugs Segment by Company

Grand Pharmaceutical (China) Co., Ltd
Innovent Biologics
Sanofi
Novartis
Merck Group
Roche
Shanghai Junshi Biosciences Co.,Ltd
Pfizer
Jiangsu Hengrui Medicine Co.,Ltd.
Bristol-Myers Squibb
BeiGene, Ltd.
Amgen
Teva Pharma
Takeda Pharma
Janssen Biotech
Genentech
Melanoma Drugs Segment by Type

Immunotherapy
Chemotherapy
Targeted Therapy
Melanoma Drugs Segment by Application

Hospitals
Clinics
Others
Melanoma Drugs Segment by Application

Hospitals
Clinics
Others
Melanoma Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Melanoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Melanoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Melanoma Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Melanoma Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

127 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Melanoma Drugs by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Immunotherapy
2.2.3 Chemotherapy
2.2.4 Targeted Therapy
2.3 Melanoma Drugs by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Hospitals
2.3.3 Clinics
2.3.4 Others
2.4 Assumptions and Limitations
3 Melanoma Drugs Breakdown Data by Type
3.1 Global Melanoma Drugs Historic Market Size by Type (2020-2025)
3.2 Global Melanoma Drugs Forecasted Market Size by Type (2026-2031)
4 Melanoma Drugs Breakdown Data by Application
4.1 Global Melanoma Drugs Historic Market Size by Application (2020-2025)
4.2 Global Melanoma Drugs Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Melanoma Drugs Market Perspective (2020-2031)
5.2 Global Melanoma Drugs Growth Trends by Region
5.2.1 Global Melanoma Drugs Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Melanoma Drugs Historic Market Size by Region (2020-2025)
5.2.3 Melanoma Drugs Forecasted Market Size by Region (2026-2031)
5.3 Melanoma Drugs Market Dynamics
5.3.1 Melanoma Drugs Industry Trends
5.3.2 Melanoma Drugs Market Drivers
5.3.3 Melanoma Drugs Market Challenges
5.3.4 Melanoma Drugs Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Melanoma Drugs Players by Revenue
6.1.1 Global Top Melanoma Drugs Players by Revenue (2020-2025)
6.1.2 Global Melanoma Drugs Revenue Market Share by Players (2020-2025)
6.2 Global Melanoma Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Melanoma Drugs Head Office and Area Served
6.4 Global Melanoma Drugs Players, Product Type & Application
6.5 Global Melanoma Drugs Manufacturers Established Date
6.6 Global Melanoma Drugs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Melanoma Drugs Market Size (2020-2031)
7.2 North America Melanoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Melanoma Drugs Market Size by Country (2020-2025)
7.4 North America Melanoma Drugs Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Melanoma Drugs Market Size (2020-2031)
8.2 Europe Melanoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Melanoma Drugs Market Size by Country (2020-2025)
8.4 Europe Melanoma Drugs Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Melanoma Drugs Market Size (2020-2031)
9.2 Asia-Pacific Melanoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Melanoma Drugs Market Size by Country (2020-2025)
9.4 Asia-Pacific Melanoma Drugs Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Melanoma Drugs Market Size (2020-2031)
10.2 South America Melanoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Melanoma Drugs Market Size by Country (2020-2025)
10.4 South America Melanoma Drugs Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Melanoma Drugs Market Size (2020-2031)
11.2 Middle East & Africa Melanoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Melanoma Drugs Market Size by Country (2020-2025)
11.4 Middle East & Africa Melanoma Drugs Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Grand Pharmaceutical (China) Co., Ltd
12.1.1 Grand Pharmaceutical (China) Co., Ltd Company Information
12.1.2 Grand Pharmaceutical (China) Co., Ltd Business Overview
12.1.3 Grand Pharmaceutical (China) Co., Ltd Revenue in Melanoma Drugs Business (2020-2025)
12.1.4 Grand Pharmaceutical (China) Co., Ltd Melanoma Drugs Product Portfolio
12.1.5 Grand Pharmaceutical (China) Co., Ltd Recent Developments
12.2 Innovent Biologics
12.2.1 Innovent Biologics Company Information
12.2.2 Innovent Biologics Business Overview
12.2.3 Innovent Biologics Revenue in Melanoma Drugs Business (2020-2025)
12.2.4 Innovent Biologics Melanoma Drugs Product Portfolio
12.2.5 Innovent Biologics Recent Developments
12.3 Sanofi
12.3.1 Sanofi Company Information
12.3.2 Sanofi Business Overview
12.3.3 Sanofi Revenue in Melanoma Drugs Business (2020-2025)
12.3.4 Sanofi Melanoma Drugs Product Portfolio
12.3.5 Sanofi Recent Developments
12.4 Novartis
12.4.1 Novartis Company Information
12.4.2 Novartis Business Overview
12.4.3 Novartis Revenue in Melanoma Drugs Business (2020-2025)
12.4.4 Novartis Melanoma Drugs Product Portfolio
12.4.5 Novartis Recent Developments
12.5 Merck Group
12.5.1 Merck Group Company Information
12.5.2 Merck Group Business Overview
12.5.3 Merck Group Revenue in Melanoma Drugs Business (2020-2025)
12.5.4 Merck Group Melanoma Drugs Product Portfolio
12.5.5 Merck Group Recent Developments
12.6 Roche
12.6.1 Roche Company Information
12.6.2 Roche Business Overview
12.6.3 Roche Revenue in Melanoma Drugs Business (2020-2025)
12.6.4 Roche Melanoma Drugs Product Portfolio
12.6.5 Roche Recent Developments
12.7 Shanghai Junshi Biosciences Co.,Ltd
12.7.1 Shanghai Junshi Biosciences Co.,Ltd Company Information
12.7.2 Shanghai Junshi Biosciences Co.,Ltd Business Overview
12.7.3 Shanghai Junshi Biosciences Co.,Ltd Revenue in Melanoma Drugs Business (2020-2025)
12.7.4 Shanghai Junshi Biosciences Co.,Ltd Melanoma Drugs Product Portfolio
12.7.5 Shanghai Junshi Biosciences Co.,Ltd Recent Developments
12.8 Pfizer
12.8.1 Pfizer Company Information
12.8.2 Pfizer Business Overview
12.8.3 Pfizer Revenue in Melanoma Drugs Business (2020-2025)
12.8.4 Pfizer Melanoma Drugs Product Portfolio
12.8.5 Pfizer Recent Developments
12.9 Jiangsu Hengrui Medicine Co.,Ltd.
12.9.1 Jiangsu Hengrui Medicine Co.,Ltd. Company Information
12.9.2 Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
12.9.3 Jiangsu Hengrui Medicine Co.,Ltd. Revenue in Melanoma Drugs Business (2020-2025)
12.9.4 Jiangsu Hengrui Medicine Co.,Ltd. Melanoma Drugs Product Portfolio
12.9.5 Jiangsu Hengrui Medicine Co.,Ltd. Recent Developments
12.10 Bristol-Myers Squibb
12.10.1 Bristol-Myers Squibb Company Information
12.10.2 Bristol-Myers Squibb Business Overview
12.10.3 Bristol-Myers Squibb Revenue in Melanoma Drugs Business (2020-2025)
12.10.4 Bristol-Myers Squibb Melanoma Drugs Product Portfolio
12.10.5 Bristol-Myers Squibb Recent Developments
12.11 BeiGene, Ltd.
12.11.1 BeiGene, Ltd. Company Information
12.11.2 BeiGene, Ltd. Business Overview
12.11.3 BeiGene, Ltd. Revenue in Melanoma Drugs Business (2020-2025)
12.11.4 BeiGene, Ltd. Melanoma Drugs Product Portfolio
12.11.5 BeiGene, Ltd. Recent Developments
12.12 Amgen
12.12.1 Amgen Company Information
12.12.2 Amgen Business Overview
12.12.3 Amgen Revenue in Melanoma Drugs Business (2020-2025)
12.12.4 Amgen Melanoma Drugs Product Portfolio
12.12.5 Amgen Recent Developments
12.13 Teva Pharma
12.13.1 Teva Pharma Company Information
12.13.2 Teva Pharma Business Overview
12.13.3 Teva Pharma Revenue in Melanoma Drugs Business (2020-2025)
12.13.4 Teva Pharma Melanoma Drugs Product Portfolio
12.13.5 Teva Pharma Recent Developments
12.14 Takeda Pharma
12.14.1 Takeda Pharma Company Information
12.14.2 Takeda Pharma Business Overview
12.14.3 Takeda Pharma Revenue in Melanoma Drugs Business (2020-2025)
12.14.4 Takeda Pharma Melanoma Drugs Product Portfolio
12.14.5 Takeda Pharma Recent Developments
12.15 Janssen Biotech
12.15.1 Janssen Biotech Company Information
12.15.2 Janssen Biotech Business Overview
12.15.3 Janssen Biotech Revenue in Melanoma Drugs Business (2020-2025)
12.15.4 Janssen Biotech Melanoma Drugs Product Portfolio
12.15.5 Janssen Biotech Recent Developments
12.16 Genentech
12.16.1 Genentech Company Information
12.16.2 Genentech Business Overview
12.16.3 Genentech Revenue in Melanoma Drugs Business (2020-2025)
12.16.4 Genentech Melanoma Drugs Product Portfolio
12.16.5 Genentech Recent Developments
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Melanoma Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 6. Global Melanoma Drugs Revenue Market Share by Type (2020-2025)
Table 7. Global Melanoma Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 8. Global Melanoma Drugs Revenue Market Share by Type (2026-2031)
Table 9. Global Melanoma Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 10. Global Melanoma Drugs Revenue Market Share by Application (2020-2025)
Table 11. Global Melanoma Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 12. Global Melanoma Drugs Revenue Market Share by Application (2026-2031)
Table 13. Global Melanoma Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 14. Global Melanoma Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 15. Global Melanoma Drugs Market Share by Region (2020-2025)
Table 16. Global Melanoma Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 17. Global Melanoma Drugs Market Share by Region (2026-2031)
Table 18. Melanoma Drugs Industry Trends
Table 19. Melanoma Drugs Industry Drivers
Table 20. Melanoma Drugs Industry Opportunities and Challenges
Table 21. Melanoma Drugs Market Restraints
Table 22. Global Top Melanoma Drugs Players by Revenue (US$ Million) & (2020-2025)
Table 23. Global Melanoma Drugs Revenue Market Share by Players (2020-2025)
Table 24. Global Melanoma Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
Table 25. Global Key Players of Melanoma Drugs, Headquarters and Area Served
Table 26. Global Melanoma Drugs Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Melanoma Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Melanoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. North America Melanoma Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 32. North America Melanoma Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 33. Europe Melanoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 34. Europe Melanoma Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 35. Europe Melanoma Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 36. Asia Pacific Melanoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 37. Asia Pacific Melanoma Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 38. Asia Pacific Melanoma Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 39. South America Melanoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 40. South America Melanoma Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 41. South America Melanoma Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 42. Middle East & Africa Melanoma Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Middle East & Africa Melanoma Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 44. Middle East & Africa Melanoma Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 45. Grand Pharmaceutical (China) Co., Ltd Company Information
Table 46. Grand Pharmaceutical (China) Co., Ltd Business Overview
Table 47. Grand Pharmaceutical (China) Co., Ltd Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 48. Grand Pharmaceutical (China) Co., Ltd Melanoma Drugs Product Portfolio
Table 49. Grand Pharmaceutical (China) Co., Ltd Recent Developments
Table 50. Innovent Biologics Company Information
Table 51. Innovent Biologics Business Overview
Table 52. Innovent Biologics Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 53. Innovent Biologics Melanoma Drugs Product Portfolio
Table 54. Innovent Biologics Recent Developments
Table 55. Sanofi Company Information
Table 56. Sanofi Business Overview
Table 57. Sanofi Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 58. Sanofi Melanoma Drugs Product Portfolio
Table 59. Sanofi Recent Developments
Table 60. Novartis Company Information
Table 61. Novartis Business Overview
Table 62. Novartis Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 63. Novartis Melanoma Drugs Product Portfolio
Table 64. Novartis Recent Developments
Table 65. Merck Group Company Information
Table 66. Merck Group Business Overview
Table 67. Merck Group Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 68. Merck Group Melanoma Drugs Product Portfolio
Table 69. Merck Group Recent Developments
Table 70. Roche Company Information
Table 71. Roche Business Overview
Table 72. Roche Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 73. Roche Melanoma Drugs Product Portfolio
Table 74. Roche Recent Developments
Table 75. Shanghai Junshi Biosciences Co.,Ltd Company Information
Table 76. Shanghai Junshi Biosciences Co.,Ltd Business Overview
Table 77. Shanghai Junshi Biosciences Co.,Ltd Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 78. Shanghai Junshi Biosciences Co.,Ltd Melanoma Drugs Product Portfolio
Table 79. Shanghai Junshi Biosciences Co.,Ltd Recent Developments
Table 80. Pfizer Company Information
Table 81. Pfizer Business Overview
Table 82. Pfizer Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 83. Pfizer Melanoma Drugs Product Portfolio
Table 84. Pfizer Recent Developments
Table 85. Jiangsu Hengrui Medicine Co.,Ltd. Company Information
Table 86. Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
Table 87. Jiangsu Hengrui Medicine Co.,Ltd. Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 88. Jiangsu Hengrui Medicine Co.,Ltd. Melanoma Drugs Product Portfolio
Table 89. Jiangsu Hengrui Medicine Co.,Ltd. Recent Developments
Table 90. Bristol-Myers Squibb Company Information
Table 91. Bristol-Myers Squibb Business Overview
Table 92. Bristol-Myers Squibb Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 93. Bristol-Myers Squibb Melanoma Drugs Product Portfolio
Table 94. Bristol-Myers Squibb Recent Developments
Table 95. BeiGene, Ltd. Company Information
Table 96. BeiGene, Ltd. Business Overview
Table 97. BeiGene, Ltd. Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 98. BeiGene, Ltd. Melanoma Drugs Product Portfolio
Table 99. BeiGene, Ltd. Recent Developments
Table 100. Amgen Company Information
Table 101. Amgen Business Overview
Table 102. Amgen Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 103. Amgen Melanoma Drugs Product Portfolio
Table 104. Amgen Recent Developments
Table 105. Teva Pharma Company Information
Table 106. Teva Pharma Business Overview
Table 107. Teva Pharma Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 108. Teva Pharma Melanoma Drugs Product Portfolio
Table 109. Teva Pharma Recent Developments
Table 110. Takeda Pharma Company Information
Table 111. Takeda Pharma Business Overview
Table 112. Takeda Pharma Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 113. Takeda Pharma Melanoma Drugs Product Portfolio
Table 114. Takeda Pharma Recent Developments
Table 115. Janssen Biotech Company Information
Table 116. Janssen Biotech Business Overview
Table 117. Janssen Biotech Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 118. Janssen Biotech Melanoma Drugs Product Portfolio
Table 119. Janssen Biotech Recent Developments
Table 120. Genentech Company Information
Table 121. Genentech Business Overview
Table 122. Genentech Revenue in Melanoma Drugs Business (2020-2025) & (US$ Million)
Table 123. Genentech Melanoma Drugs Product Portfolio
Table 124. Genentech Recent Developments
Table 125. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Melanoma Drugs Product Image
Figure 5. Global Melanoma Drugs Market Size Comparison by Type (2025-2031) & (US$ Million)
Figure 6. Global Melanoma Drugs Market Share by Type: 2024 VS 2031
Figure 7. Immunotherapy Product
Figure 8. Chemotherapy Product
Figure 9. Targeted Therapy Product
Figure 10. Global Melanoma Drugs Market Size by Application (2025-2031) & (US$ Million)
Figure 11. Global Melanoma Drugs Market Share by Application: 2024 VS 2031
Figure 12. Hospitals Product
Figure 13. Clinics Product
Figure 14. Others Product
Figure 15. Global Melanoma Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Melanoma Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Melanoma Drugs Market Share by Region: 2024 VS 2031
Figure 18. Global Melanoma Drugs Market Share by Players in 2024
Figure 19. Global Melanoma Drugs Manufacturers Established Date
Figure 20. Global Top 5 and 10 Melanoma Drugs Players Market Share by Revenue in 2024
Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 22. North America Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Melanoma Drugs Market Share by Country (2020-2031)
Figure 24. United States Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Mexico Melanoma Drugs Market Share by Country (2020-2031)
Figure 27. Europe Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Europe Melanoma Drugs Market Share by Country (2020-2031)
Figure 29. Germany Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. France Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. U.K. Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Italy Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Spain Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Russia Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Netherlands Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Nordic Countries Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Melanoma Drugs Market Share by Country (2020-2031)
Figure 39. China Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Japan Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. South Korea Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. India Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. India Melanoma Drugs Market Share by Country (2020-2031)
Figure 44. Australia Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. China Taiwan Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Southeast Asia Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. South America Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. South America Melanoma Drugs Market Share by Country (2020-2031)
Figure 49. Brazil Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Argentina Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Chile Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Colombia Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Peru Melanoma Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Grand Pharmaceutical (China) Co., Ltd Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 55. Innovent Biologics Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 56. Sanofi Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 57. Novartis Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 58. Merck Group Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 59. Roche Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 60. Shanghai Junshi Biosciences Co.,Ltd Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 61. Pfizer Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 62. Jiangsu Hengrui Medicine Co.,Ltd. Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 64. BeiGene, Ltd. Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 65. Amgen Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 66. Teva Pharma Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 67. Takeda Pharma Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 68. Janssen Biotech Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
Figure 69. Genentech Revenue Growth Rate in Melanoma Drugs Business (2020-2025)
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.